Published in Women's Health Weekly, February 9th, 2006
"Concurrent chemoradiotherapy is the standard of care for locally advanced cervix cancer; the optimal chemotherapy regimen is not yet defined. This trial was designed to compare the outcome of PVI FU with standard weekly cisplatin and concurrent radiation therapy (RT). Patients with stage IIB, IIIB, and IVA cervical cancer with clinically negative aortic nodes were eligible," scientists in the United States reported.
"Pelvic FIT dose was 45 Gy with a parametrial boost to involved sides of 5.4 to 9 Gy,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly